The presence of BRCA mutation in pancreatic NETs aids in determining the response to platinum-based therapy [18], whereas the presence of BRCA mutation in prostatic NECs aids in determining the response to poly [ADP-ribose] polymerase 1 inhibitors [20]. The gene discussed is PARP1; the disease is pancreatic neuroendocrine tumor.